The U.S. Constitution vs. the U.S. Department of Health vs. the U.S. Drug Enforcement Agency

If nothing else we can all be certain that the U.S. Federal government can no longer agree on the value of Cannabis.

Should an agreement be reached between health officials and law enforcement officials before prohibiting the use of Cannabis?

The following evidence suggests, any law prohibiting the use of anything can be created and strictly enforced in the absence of agreement. Awareness and understanding aside, it would appear that whomever has the gun, has the power when it comes to law making and law enforcement in the U.S.

This is the not the promise of the U.S. Constitution which states in it’s Preamble,

“We the People of the United States, in Order to form a more perfect Union, establish Justice, insure domestic Tranquility, provide for the common defense, promote the general Welfare, and secure the Blessings of Liberty to ourselves and our Posterity, do ordain and establish this Constitution for the United States of America.” –U.S. Constitution

DEA’S POSITION ON MARIJUANA
“Marijuana is properly categorized under Schedule I of the Controlled Substances Act (CSA), 21 U.S.C. § 801, et seq. The clear weight of the currently available evidence supports this
classification, including evidence that smoked marijuana has a high potential for abuse, has no accepted medicinal value in treatment in the United States, and evidence that there is a general lack of accepted safety for its use even under medical supervision.” – U.S. Drug Enforcement Agency

U.S. Department of Health’s Position on Marijuana

“ABSTRACT – Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.” – U.S. Patent#US6630507 B1